Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis Flex et al.
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Supplementary Figure S5 . Abolished GAP-stimulated GTP hydrolysis of the RRAS G39dup mutant. 4 Unspecified bone tumour (left leg) diagnosed during childhood. 5 AML suspected to be secondary to JMML, with onset at 13 years (Supplementary Table S3 ). The condition was not associated with any germline/somatic mutation affecting previously identified RASopathy genes. Several complications occurred during treatment (renal failure, pulmonar infection, vein-occlusive disease), without complete remission. Death occurred at age of 16 by recurrence of the disease after 2 years of palliative treatment. Table S3 . Haematological features associated with germline or somatically acquired RRAS mutations. Mutations characterise a subset of myeloid neoplasms with classical features of JMML (i.e., monocytosis, low blast counts, presence of circulating myeloid progenitors, and elevated basophil counts) combined with atypical features, including late onset and rapid progression to AML. The latter, along with monosomy 7, are reminiscent of AML with myelodysplasia-related changes. G27dup results from the three-nucleotide insertion, c.82_83insGCG, corresponding to the RASopathy causative c.116_118dup in RRAS. The concentration at which the plasmid has been injected is reported in parenthesis. Worms were grown at 20 °C and heat-shocked at early L3 stage. Isogenic worms that had lost the transgene were cloned separately and used as controls. N indicates the number of animals scored. Pvl is the percent of adult worms with a protruding vulva. Egl is the percent of animals with an increased number of eggs retained in the uterus (N > 22). Bag is the percent of bag-of-worms animals counted up to 6 days post-fertilisation. [1] [2] [3] [4] Statistical significance of comparisons with worms expressing ras-1 WT at the corresponding dose of injection ( 1 P < 0.05; 2 P < 0.005; 3 P < 0.0005; 4 P < 0.01). P values were calculated using 2-Tail Fisher's Exact Test.
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